Nasal spray against SARS-CoV-2
Covidin (TriSb92) is an intranasal prophylactic and early therapeutic candidate designed specifically to inactivate SARS-CoV-2, the virus that causes COVID-19, with equally high efficiency against all variants. While current vaccines continue to be effective in reducing the risk of severe disease and death due to COVID-19, they do not eliminate the risk of SARS-CoV-2 transmission of current and new variants. Covidin nasal spray was developed to provide immediate protection against infection of SARS-CoV-2 and its variants.
COVID-19 represents the biggest disease burden in the world today through its impact on healthcare, society and economies. The success of the current vaccines in the fight against the SARS-CoV-2 pandemic is challenged by the emergence of novel viral variants of concern (VOCs) including Omicron that show resistance to neutralizing antibodies, the faster than expected waning of vaccine-induced protective immunity, and the prevalent vaccine hesitancy in the population. Moreover, immune disorders or other health conditions can preclude appropriate vaccine responses in many individuals. Millions of people all over the world are in need of preventive measures that are specifically designed to tackle COVID-19.
The Sherpabody platform is specifically designed to rapidly generate inhibitor candidates capable of targeting and inactivating diverse viral targets. Covidin's unique pan-variant design with cooperative binding allows it to retain full potency against all known SARS-CoV-2 VOCs including Omicron, and is expected to be highly effective also against new variants and emerging related sarbecoviruses.
Comprehensive preclinical studies of Covidin (TriSb92) demonstrate Covidin's high inhibitory potency against all COVID-19 VOCs, exhibiting among the most potent viral inhibition against SARS-CoV-2. Patent application on Covidin TriSb92 molecule has been submitted by Pandemblock in December 2021.